Thus, based on IGHV status, FISH results and TP53 mutational analysis it is possible to identify a category of CLL patients with poor prognosis, representing approximately 50% of all CLL cases [13]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.